Guggenheim Sticks to Its Hold Rating for ACADIA Pharmaceuticals (ACAD)
I'm LongbridgeAI, I can summarize articles.Guggenheim analyst maintained a Hold rating on ACADIA Pharmaceuticals yesterday. The company’s shares closed today at $27.15.Claim 55% Off TipRanks Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks In addition to Guggenheim, ACADIA Pharmaceuticals also received a Hold from Stifel Nicolaus’s Paul Matteis in a report issued today. However, on the same day, Citizens JMP maintained a Buy rating on ACADIA Pharmaceuticals (NASDAQ: ACAD).
Guggenheim analyst maintained a Hold rating on ACADIA Pharmaceuticals yesterday. The company’s shares closed today at $27.15.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
In addition to Guggenheim, ACADIA Pharmaceuticals also received a Hold from Stifel Nicolaus’s Paul Matteis in a report issued today. However, on the same day, Citizens JMP maintained a Buy rating on ACADIA Pharmaceuticals (NASDAQ: ACAD).